| scholarly article | Q13442814 |
| P50 | author | Stefania Pittaluga | Q87358458 |
| Maryalice Stetler-Stevenson | Q90926259 | ||
| Jade Jones | Q108653266 | ||
| Christian Geisler | Q41603005 | ||
| Carsten Utoft Niemann | Q55445012 | ||
| P2093 | author name string | Xin Tian | |
| Neal S Young | |||
| Thomas E Hughes | |||
| Adrian Wiestner | |||
| Nakhle Saba | |||
| Irina Maric | |||
| Katherine R Calvo | |||
| Richard Childs | |||
| Georg Aue | |||
| Sarah E M Herman | |||
| Diane C Arthur | |||
| Gerald Marti | |||
| Janet Valdez | |||
| Mohammed Z H Farooqui | |||
| Susan Soto | |||
| Constance Yuan | |||
| Yuh Shan Lee | |||
| Sabrina Martyr | |||
| Andrew Lipsky | |||
| Lone B Pedersen | |||
| P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
| Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial | Q27851638 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
| Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion | Q33978930 | ||
| Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia | Q34009041 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. | Q34289493 | ||
| Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? | Q34769213 | ||
| Ibrutinib resistance in chronic lymphocytic leukemia | Q35881570 | ||
| Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia | Q36462375 | ||
| Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease | Q37474415 | ||
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
| What is the best frontline therapy for patients with CLL and 17p deletion? | Q37820433 | ||
| Bruton tyrosine kinase (BTK) and its role in B-cell malignancy | Q37997075 | ||
| Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial | Q38001693 | ||
| 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach | Q38096537 | ||
| How the microenvironment wires the natural history of chronic lymphocytic leukemia | Q38119790 | ||
| Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. | Q38232480 | ||
| BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity | Q39056302 | ||
| Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial | Q42994283 | ||
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | Q53061290 | ||
| P433 | issue | 2 | |
| P921 | main subject | lymphocyte | Q715347 |
| leukemia | Q29496 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| ibrutinib | Q5984881 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 169-176 | |
| P577 | publication date | 2014-12-31 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | |
| P478 | volume | 16 |
| Q90262439 | "Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia |
| Q54979456 | A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. |
| Q47112085 | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy. |
| Q35794593 | A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia |
| Q47615956 | Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. |
| Q39154824 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). |
| Q42383009 | Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib |
| Q26765624 | BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia |
| Q59126180 | Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia |
| Q50121608 | Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. |
| Q41848521 | Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia |
| Q33798525 | Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number |
| Q37641736 | Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells |
| Q89267533 | Choosing frontline chemoimmunotherapy for CLL |
| Q39263974 | Chronic lymphocytic leukaemia genomics and the precision medicine era. |
| Q91666607 | Chronic lymphocytic leukaemia: from genetics to treatment |
| Q91934079 | Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options |
| Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
| Q37113544 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way |
| Q57034197 | Chronic lymphocytic leukemia treatment algorithm 2018 |
| Q38663689 | Clinical Impact of the 2016 Update to the WHO Lymphoma Classification |
| Q38962267 | Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation |
| Q48191937 | Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide |
| Q40397638 | Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia |
| Q46074725 | Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. |
| Q92347508 | Cross-talk between Myc and p53 in B-cell lymphomas |
| Q89777331 | Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q39129372 | Current Treatment of Chronic Lymphocytic Leukemia. |
| Q64092413 | Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment |
| Q52684522 | Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study. |
| Q36799831 | Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. |
| Q39363409 | Diagnosis and classification of hematologic malignancies on the basis of genetics. |
| Q36759124 | Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study |
| Q37290270 | Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. |
| Q38792651 | Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States |
| Q89459131 | Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty |
| Q92244497 | Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects |
| Q49731233 | Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program |
| Q92001899 | Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review |
| Q38543771 | Emerging immunological drugs for chronic lymphocytic leukemia |
| Q39158411 | Emerging protein kinase inhibitors for treating pancreatic cancer |
| Q91272431 | European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms |
| Q89004911 | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials |
| Q54108755 | Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. |
| Q38764077 | Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting |
| Q38881164 | Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia |
| Q47424531 | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
| Q38817591 | From identification of the BTK kinase to effective management of leukemia. |
| Q52685587 | Frontline Therapy of CLL: Evolving Treatment Paradigm. |
| Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
| Q38394750 | Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. |
| Q39016282 | How I manage ibrutinib-refractory chronic lymphocytic leukemia |
| Q47340234 | How should we sequence and combine novel therapies in CLL? |
| Q90466660 | IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study |
| Q47780043 | Ibrutinib and its use in the treatment of chronic lymphocytic leukemia |
| Q36490049 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia |
| Q47120457 | Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature |
| Q46689848 | Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia |
| Q38956893 | Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study |
| Q52848520 | Ibrutinib holds promise for patients with 17p deletion CLL. |
| Q38545545 | Ibrutinib in B lymphoid malignancies |
| Q30252869 | Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib |
| Q42335810 | Ibrutinib in the real world patient: many lights and some shades. |
| Q90315525 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial |
| Q37688589 | Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. |
| Q38524270 | Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target |
| Q46529579 | Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review |
| Q89941567 | Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab |
| Q90534414 | Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes |
| Q49180606 | Ibrutinib-associated pityriasis rosea-like rash |
| Q61799313 | Immunochemotherapy for Richter syndrome: current insights |
| Q42344564 | Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification |
| Q54979047 | Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. |
| Q37489992 | Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients |
| Q47793348 | Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada |
| Q42368314 | Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach |
| Q36337598 | Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q101121282 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances |
| Q36219647 | Initial treatment of CLL: integrating biology and functional status |
| Q36437030 | Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. |
| Q37697093 | Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations |
| Q26781895 | Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia |
| Q90215825 | Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema |
| Q48358731 | Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. |
| Q57174839 | Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) |
| Q37641245 | Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules |
| Q92176355 | Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab |
| Q47674917 | MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia |
| Q92740078 | Machine learning can identify newly diagnosed patients with CLL at high risk of infection |
| Q38943877 | Magic pills: new oral drugs to treat chronic lymphocytic leukemia. |
| Q50110556 | Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. |
| Q38550810 | Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment |
| Q52801615 | Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. |
| Q36550468 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia |
| Q92523156 | Multiset sparse partial least squares path modeling for high dimensional omics data analysis |
| Q57031907 | Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP |
| Q53454991 | Novel agents versus chemotherapy as frontline treatment of CLL. |
| Q38594364 | Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide |
| Q53164083 | Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. |
| Q86174587 | PROLONGing remissions in patients with CLL |
| Q36253983 | Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q38851368 | Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future? |
| Q38544216 | Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly |
| Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
| Q39002032 | Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice |
| Q92152577 | Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL |
| Q38650361 | Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare? |
| Q92633734 | Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib |
| Q38997367 | Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia |
| Q36022532 | Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia |
| Q30240258 | Prognostication of chronic lymphocytic leukemia in the era of new agents |
| Q38806070 | Programming the immune checkpoint to treat hematologic malignancies. |
| Q92355034 | Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis |
| Q31097476 | Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group |
| Q38862525 | Recent advances in therapy of chronic lymphocytic leukaemia |
| Q64949407 | Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia. |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q30240243 | Sequencing of chronic lymphocytic leukemia therapies. |
| Q38691282 | Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. |
| Q38917132 | Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. |
| Q60922686 | Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia |
| Q36161658 | Specificity and biologic activities of novel anti-membrane IgM antibodies |
| Q37742056 | Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia |
| Q93376490 | TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib |
| Q27002528 | Targeted therapies in CLL: mechanisms of resistance and strategies for management |
| Q38654101 | Targeting B Cell Signaling in Chronic Lymphocytic Leukemia |
| Q49951221 | Targeting B cell receptor signalling in cancer: preclinical and clinical advances |
| Q91911728 | Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003 |
| Q58613953 | Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies |
| Q27025812 | Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib |
| Q53764598 | Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. |
| Q46566477 | The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia |
| Q26749214 | The clinical implications of gene mutations in chronic lymphocytic leukaemia |
| Q47102996 | The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. |
| Q90569013 | The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia |
| Q38748645 | The molecular pathogenesis of chronic lymphocytic leukaemia |
| Q28075504 | The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia |
| Q26775506 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia |
| Q30243968 | The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia |
| Q41708887 | The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. |
| Q90455044 | Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study |
| Q47399742 | Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia |
| Q36172601 | Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo |
| Q53237596 | Understanding cancer cell survival is key to patient survival. |
| Q41310328 | Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis |
| Q33566747 | Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors |
| Q90071201 | Venetoclax for the Treatment of Chronic Lymphocytic Leukemia |
| Q47875923 | Venetoclax for the treatment of chronic lymphocytic leukemia. |
| Q33432228 | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study |
| Q48211381 | Ventricular arrhythmias and sudden death in patients taking ibrutinib |
| Q39154057 | What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? |
| Q99563209 | [Clinical value of PET/CT in the diagnosis of Richter syndrome] |
| Q39694093 | p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. |
Search more.